Gerhard Sperl
- Pharmacology top 1%
- Molecular Biology
- Genetics top 5%
- Oncology top 10%
- Cancer Research top 10%
- Co-authors
- Rifat PamukcuGary A. PiazzaKlaus BrendelPaul H. GrossN S ParankaDavid S. AlbertsRandall W. BurtWilliam J. Thompson
- Topics
- Estrogen and related hormone effects (4 papers)Inflammatory mediators and NSAID effects (4 papers)Phosphodiesterase function and regulation (3 papers)
- Cited by
- PharmacologyGeneticsCancer Research
- Journals
- GastroenterologyJournal of Pharmacology and Experimental TherapeuticsBiochemical Pharmacology
- Partner nations
- United StatesGermany
In The Last Decade
Gerhard Sperl
15 papers receiving 1.4k citations
Peers
Comparison fields: 5 of 81
- Pharmacology 770
- Molecular Biology 567
- Genetics 432
- Oncology 268
- Cancer Research 231
Countries citing papers authored by Gerhard Sperl
This map shows the geographic impact of Gerhard Sperl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gerhard Sperl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gerhard Sperl more than expected).
Fields of papers citing papers by Gerhard Sperl
This network shows the impact of papers produced by Gerhard Sperl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gerhard Sperl. The network helps show where Gerhard Sperl may publish in the future.
Co-authorship network of co-authors of Gerhard Sperl
This figure shows the co-authorship network connecting the top 25 collaborators of Gerhard Sperl. A scholar is included among the top collaborators of Gerhard Sperl based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gerhard Sperl. Gerhard Sperl is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 7 | |
| 2 | 6 | |
| 3 | 61 | |
| 4 | CP248, a derivative of exisulind, causes growth inhibition, mitotic arrest, and abnormalities in microtubule polymerization in glioma cells. | 20 |
| 5 | 7 | |
| 6 | 74 | |
| 7 | Exisulind induction of apoptosis involves guanosine 3',5'-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin. | 268 |
| 8 | 2 | |
| 9 | 180 | |
| 10 | 1 | |
| 11 | Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. | 315 |
| 12 | Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis. | 378 |
| 13 | Inhibition of mammary carcinogenesis in rats by sulfone metabolite of sulindac. | 63 |
| 14 | 8 | |
| 15 | 2 |
About Gerhard Sperl
Gerhard Sperl is a scholar working on Pharmacology, Toxicology and Organic Chemistry, having authored 15 papers that have together received 1.4k indexed citations. Recurring topics across this work include Estrogen and related hormone effects (4 papers), Inflammatory mediators and NSAID effects (4 papers) and Phosphodiesterase function and regulation (3 papers). The work is most often cited by research in Pharmacology (770 citations), Genetics (432 citations) and Cancer Research (231 citations). Gerhard Sperl has collaborated with scholars based in United States and Germany. Frequent co-authors include Rifat Pamukcu, Gary A. Piazza, Klaus Brendel, Paul H. Gross, N S Paranka, David S. Alberts, Randall W. Burt, William J. Thompson, Mary F. Krutzsch and John Fetter. Their work appears in journals such as Gastroenterology, Journal of Pharmacology and Experimental Therapeutics and Biochemical Pharmacology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.